Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian
GET TICKETS

Biotech ETFs Hit New 2015 Highs

Share:
Biotech ETFs Hit New 2015 Highs

The biotech momentum story continues to be one of the most persistent themes over the last several years. The diversified indices that track these companies have been consistent market leaders, and investors that have stuck with these stocks have been richly rewarded.

On Thursday, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) hit a new all-time high as it surged more than 3 percent intra-day. This ETF is the largest dedicated biotech industry fund, with nearly $9 billion in total assets.

Top Biotech ETF

IBB tracks a market-cap weighted index of top healthcare names such as Gilead Sciences, Inc. (NASDAQ: GILD) and Amgen, Inc. (NASDAQ: AMGN). These companies are engaged in the fight to cure diseases and develop lifesaving drugs, but the story that investors are cheering is their year-to-date performance.

Related Link: Suntrust's 5 Biotech Picks For The Next 6 Months

So far in 2015, IBB has gained more than 24 percent and is 51 percent higher over the last full year. The jump in IBB is now on par with Guggenheim Solar ETF (NYSE: TAN), as the two top-performing industry groups so far this year."

ibb.png

IBB's Peer

Another fund that has quickly staked out a name for itself in the biotech group is the ALPS Medical Breakthroughs ETF (NYSE: SBIO). This ETF tracks 73 underlying stocks with market capitalizations less than $5 billion.

The smaller company focus of SBIO is overlaid with fundamental screens to ensure sustainable cash flow and clinical trial suitability. In addition, this ETF has 25 percent of its portfolio dedicated to pharmaceutical stocks.

SBIO debuted in late 2014 and has amassed $92 million in total assets. So far this year, this ETF has gained over 44 percent and continues to be one of the top performing funds in its class.

sbio_0.png

Related Link: Hedge Funds Buying Biotech IPO Operated By Ex-Fund Manager

Tailwind For Broad-Based ETFs

It’s also worth noting that the biotechnology theme has been a tailwind for broad-based ETFs such as the Health Care SPDR (ETF) (NYSE: XLV) and PowerShares QQQ Trust, Series 1 (ETF) (NASDAQ: QQQ). 

Some experts worry that this industry group may be reaching bubble territory, yet prices continue to surge higher nonetheless. IBB underwent two brief bouts of volatility this year in March and April that it ultimately overcame in a convincing manner.

Image Credit: Public Domain

Posted-In: Biotech Sector ETFs Broad U.S. Equity ETFs Top Stories Trading Ideas ETFs Best of Benzinga

 

Related Articles (AMGN + GILD)

View Comments and Join the Discussion!
Lightning Fast
Market News Service
$199 Free 14 Day Trial

Why Nokia Has Multiple Catalysts, Multiple Suitors For HERE Business

Live Cattle Lower